Biotech Values

[genisi]

One point on efficacy: belatacept was compared to cylcosporine not to tacrolimus, which is used more often, considered more potent and does not harm kidney function as much. Also, the panel highlighted safety problems seen in belatacept's clinical studies - high acute rejection rate, post-transplant lymphoproliferative disease and PML. lastly, belatacept has another commercial disadvantage as it is given iv whereas both tacrolimus and cylcosporine are given orally.